Allogene Therapeutics
South San Francisco
CA
United States
194 articles about Allogene Therapeutics
-
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
3/23/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with anti-BCMA CAR T cells from patients with multiple myeloma.
-
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
3/10/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
-
Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
-
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
3/1/2022
Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance.
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/23/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2021.
-
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
2/16/2022
Allogene Therapeutics, Inc. today announced that it will report fourth quarter and year-end 2021 financial results on Wednesday, February 23, 2022 after the close of the market.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
1/11/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), and Antion Biosciences, today announced that they have entered into an exclusive collaboration and global license agreement for Antion’s miRNA technology (miCAR™) to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products.
-
California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
-
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
-
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
1/10/2022
Allogene Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on all of the Company’s AlloCAR T clinical trials.
-
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 12:45 p.m. Pacific Time/3:45 p.m. Eastern Time.
-
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
12/15/2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it entered into a lease agreement to expand its headquarters in South San Francisco, California.
-
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
12/13/2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced positive updated results from the Phase 1 UNIVERSAL study of single dose ALLO-715 in relapsed/refractory (r/r) multiple myeloma.
-
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
12/13/2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today reported updated data from two Phase 1 clinical trials (ALPHA and ALPHA2) of its lead anti-CD19 AlloCAR T therapy programs (ALLO-501 and ALLO-501A) at the 63rd American Society of Hematology (ASH) Annual Meeting.
-
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
12/1/2021
Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET.
-
Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
11/4/2021
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer announced that it will present updated data from its blood cancer portfolio at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.
-
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
11/4/2021
Allogene Therapeutics, Inc. today provided a corporate update and reported financial results for the quarter ended September 30, 2021.
-
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
-
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
10/28/2021
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the close of the market.